TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24566991
Drug: Twice-a-week supervised
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-week supervised aerobic and resistance training plus exercise counseling (EXE)
Study: 22657950
Drug: AXOS-enriched breads
Normalized name: Rhizopus stolonifer allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXOS-enriched breads (2.2 g AXOS)
Study: 19947803
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (57 patients)
Study: 17697451
Drug: Pegfilgrastim (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (100 microg/kg or a fixed dose of 6 mg)
Study: 15103534
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT) delivered by trained social workers
Study: 11153777
Drug: PET-guided management
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET-guided management (n=49; 12 PTCA, 14 CABG, 23 drug therapy)
Study: 11153777
Drug: SPECT-guided management
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPECT-guided management (n=54; 15 PTCA, 13 CABG, 26 drug therapy)
Study: 9663912
Drug: Lisinopril treatment
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril treatment after 3 and 12 months
Study: 9663912
Drug: Lisinopril plus
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril plus hydrochlorothiazide treatment after 3 and 12 months
Study: 9663912
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment after a final 4-week period
Study: 2839321
Drug: Methylcellulose 4
Normalized name: methylcellulose 475 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcellulose 4 g
Study: 2839321
Drug: Methylcellulose 1
Normalized name: methylcellulose 1500cps
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcellulose 1 g, 2 g, or 4 g
Study: 16303008
Drug: Low-dose sirolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sirolimus (SRL) with low-dose MMF
Study: 16303008
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine (CsA) with low-dose MMF
Study: 28686771
Drug: Clindamycin-BP 3.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin-BP 3.75% aqueous gel, once-daily for 12 weeks
Study: 28686771
Drug: Clindamycin-BP 3.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin-BP 3.75% aqueous gel, continued treatment for a further 12 weeks for patients with ≥50% reduction in total lesion count
Study: 28686771
Drug: Clindamycin-BP 3.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin-BP 3.75% aqueous gel
Study: 23400620
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (152 mg/d vitamin C and 50 mg/d vitamin E)
Study: 16565956
Drug: VBMCP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBMCP and high‐dose cyclophosphamide
Study: 14693058
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CTX) 3.5 g/m(2) intravenously plus rhG-CSF 5 microg x kg(‐1) x day(‐1)
Study: 14693058
Drug: Etoposide (VP-16)
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide (VP-16) 1000 mg/m(2) or 1500 mg/m(2) intravenously plus rhG-CSF 5 microg x kg(‐1) x day(‐1)
Study: 11075314
Drug: Rosiglitazone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (2 mg every 12 hours)
Study: 11075314
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg every 12 hours)
Study: 11075314
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rosiglitazone and metformin
Study: 11075314
Drug: Rosiglitazone and
Normalized name: Rosiglitazone and Glimepiride Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone and metformin (alone or in combination)
Study: 9345020
Drug: SCF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCF plus G‐CSF
Study: 9345020
Drug: SCF pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCF pretreatment followed by SCF plus G‐CSF
Study: 9345020
Drug: Control (G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (G‐CSF alone)
Study: 8177925
Drug: Piracetam (2.9,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (2.9, 4.8, and 9.6 g Nootropil UCB)
Study: 24351534
Drug: Glutamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (0.3 g/kg protein in the form of glutamine dipeptide for 10 days)
Study: 24351534
Drug: Glutamine combined
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine combined with ulinastatin (0.3 g/kg protein in the form of glutamine dipeptide for 10 days + intravenous injection of 100 kU ulinastatin every 8 hours for 7 days)
Study: 18156400
Drug: 7.5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 g/d DHA oil (3 g DHA/d)
Study: 12620949
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (CEI) with 0.15 mL x kg(‐1) x hr(‐1) 0.2% ropivacaine
Study: 12620949
Drug: Patient-controlled epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia (PCEA) with 5 mL single bolus application of R or BS every 20 min
Study: 28266704
Drug: EO/LP solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: EO/LP solution (Australian eucalyptus oil and Leptospermum petersonii); applied thrice with 7-day intervals
Study: 28266704
Drug: EO/LP solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: EO/LP solution (Australian eucalyptus oil and Leptospermum petersonii); single application
Study: 28266704
Drug: P/PB mousse
Approvals — FDA: no, EMA: no, PMDA: no
Description: P/PB mousse (pyrethrins and piperonyl butoxide); applied twice with a 7-day interval
Study: 24655542
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (eight sessions over 4 weeks)
Study: 24655542
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (after a 4-week waiting period)
Study: 22446143
Drug: ongoing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ongoing treatment
Study: 3476513
Drug: Oral rinse
Normalized name: Oral Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rinse containing 300 micrograms/ml sanguinaria extract
Study: 3476513
Drug: Supragingival irrigation
Normalized name: ALCOHOL 80 mL in 100 mL INTRAGINGIVAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supragingival irrigation with dilute solutions of sanguinaria (22.5 micrograms/ml and 90 micrograms/ml)
Study: 26354567
Drug: Atorvastatin (intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (intervention group)
Study: 16798445
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine with fentanyl 2 microg/mL (RF-group)
Study: 12884990
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 10 mg and fentanyl 25 microg (upright for 15 min)
Study: 12884990
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 15 mg (immediately positioned supine)
Study: 8827897
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin K1 (N = 13)
Study: 8827897
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin K1 (N = 16)
Study: 26365555
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (cholecalciferol) 100,000 IU (2.5 mg) monthly for an estimated median of 3.3 years (range 2.5‐4.2 years)
Study: 12637463
Drug: Bexarotene 200
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bexarotene 200 mg/m²/d
Study: 12637463
Drug: Bexarotene 500
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bexarotene 500 mg/m²/d
Study: 10593328
Drug: Oral immunonutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunonutrition (an arginine‐, RNA‐, and omega3 fatty acid‐supplemented diet) for 5 days preoperatively and enteral feeding for 10 days postoperatively
Study: 10593328
Drug: Isoenergetic control
Normalized name: Octisalate 0.05 g in 1 mL / Avobenzone 0.03 g in 1 mL / Octinoxate 0.029 g in 1 mL / Octocrylene 0.022 g in 1 mL TOPICAL LOTION [For Men Maca Root Energetic Face Protector SPF 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoenergetic control diet (1 L/d) for 5 days preoperatively and enteral feeding for 10 days postoperatively
Study: 1860327
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at 5 micrograms/kg.min
Study: 1860327
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at 10 micrograms/kg.min
Study: 1860327
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at all three rates (2.5, 5, and 10 micrograms/kg.min)
Study: 6839635
Drug: Cimetidine 1200
Normalized name: cimetidine 1200 mg-0.9%/500 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1200 mg a day
Study: 6839635
Drug: Cimetidine 2400
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 2400 mg a day
Study: 31107300
Drug: Nucleoside reverse
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside reverse transcriptase inhibitors
Study: 26805558
Drug: 20 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 minutes post-infusion scalp cooling
Study: 26805558
Drug: 45 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 minutes post-infusion scalp cooling
Study: 20073213
Drug: Integrative Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Chinese and Western medicine (Yuntu recipe)
Study: 20073213
Drug: Western medical
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medical supportive treatment (fluid infusion)
Study: 8304565
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg pentamidine isethionate, administered in four every-other-day injections
Study: 8304565
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg pentamidine isethionate, administered in four every-other-day injections
Study: 8304565
Drug: Standard Glucantime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Glucantime therapy
Study: 28765032
Drug: Swaddling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swaddling with oral administration of 0.2 ml of 24% sucrose
Study: 28765032
Drug: Swaddling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swaddling with oral administration of breast milk
Study: 28765032
Drug: Swaddling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swaddling with oral administration of distilled water (control)
Study: 22965458
Drug: Low-dose spinal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose spinal anaesthesia (8-mg hyperbaric bupivacaine 0.5% with fentanyl 20 μg)
Study: 8554246
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy with 3 or more daily insulin injections or continuous subcutaneous insulin infusion, guided by 4 or more glucose tests per day
Study: 8554246
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with 1 or 2 daily insulin injections
Study: 1992534
Drug: 480 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg/d megestrol acetate
Study: 1992534
Drug: 960 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 960 mg/d megestrol acetate
Study: 1992534
Drug: Low-dose megestrol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose megestrol acetate
Study: 6411382
Drug: Topical cromoglycates
Normalized name: cromoglycate
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical cromoglycates
Study: 28953501
Drug: Neostigmine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 40 μg/kg
Study: 14617222
Drug: Lispro insulin
Normalized name: Lispro insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lispro insulin + NPH insulin
Study: 14617222
Drug: Lispro insulin
Normalized name: Lispro insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lispro insulin + metformin
Study: 14617222
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin + NPH insulin
Study: 10685722
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg (Ate)
Study: 9086133
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day hydroxyurea
Study: 9086133
Drug: 1000 mg/day
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/day hydroxyurea
Study: 9086133
Drug: Control (didanosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (didanosine therapy only)
Study: 30664008
Drug: Subcutaneous interferon‐α
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon‐α (IFN‐α) 9×10 IU/m, n=125
Study: 30664008
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous interleukin-2 (IL‐2) 9×10 IU/m, n=125
Study: 30664008
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous interleukin-2 (IL‐2), n=125
Study: 30664008
Drug: Subcutaneous interferon‐α
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon‐α (IFN‐α), n=125
Study: 30040818
Drug: Tailored multifaceted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored multifaceted intervention (n = 154) including physiotherapist-led vestibular rehabilitation (35%), internet-based cognitive-behavioral therapy (19%), Otago home-based exercise program (24%), and medical management (40%)
Study: 23788468
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM) with intravenous (IV) fentanyl
Study: 19995933
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tafenoquine
Study: 19995933
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg mefloquine
Study: 17976222
Drug: Candesartan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (8 mg po/d, given for 6‐8 days before surgery)
Study: 16629348
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (150 to 300 mg daily)
Study: 14667956
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of rosuvastatin 40 mg
Study: 14667956
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of rosuvastatin 8 mg over 4 hours
Study: 11027740
Drug: Budesonide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (mean daily dose of 412 microg, mean cumulative dose of 1.35 g over 9.2 years)
Study: 11027740
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (asthma patients who never received inhaled corticosteroids)
Study: 9203786
Drug: Erythromycin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (50 mg/kg per day in four divided doses)
Study: 9203786
Drug: Trimethoprim-sulphamethoxazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulphamethoxazole (10 mg/kg per day of trimethoprim and 50 mg/kg per day of sulphamethoxazole in two divided doses for five days)
Study: 1306084
Drug: Supro isolated
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supro isolated soy protein (1.5 g/kg/day, 8 weeks)
Study: 3511977
Drug: Single administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administration of E. coli AZ (group A)
Study: 3511977
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C) receiving no administration
Study: 31884246
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (placebo)
Study: 29885082
Drug: Resveratrol (RSV)
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (RSV) 500 mg 3 times daily for 6 months
Study: 21451421
Drug: Eplerenone (100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (100-300 mg once daily)
Study: 21451421
Drug: Spironolactone (75-225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (75-225 mg once daily)
Study: 12378634
Drug: OAM: metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAM: metronidazole 500 mg bid, amoxicillin 1 g bid, omeprazole 20 mg bid
Study: 12378634
Drug: OAA: azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAA: azithromycin 1 g od for the first 3 days, amoxicillin 1 g bid, omeprazole 20 mg bid
Study: 12492615
Drug: In-patient pharmaceutical
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-patient pharmaceutical counselling with MIDS and medicine reminder card
Study: 30944269
Drug: Acarbose 300
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 300 mg/d
Study: 18823203
Drug: Evolved agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolved agent
Study: 16332231
Drug: beta‐TCP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐TCP + 0.3 mg/ml rhPDGF‐BB in buffer
Study: 16332231
Drug: beta‐TCP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐TCP + 1.0 mg/ml rhPDGF‐BB in buffer
Study: 12215691
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg intravenous ketoprofen 30 minutes before surgical incision (Group I)
Study: 12215691
Drug: Immediate post-surgical
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate post-surgical intravenous ketoprofen (Group II)
Study: 2576216
Drug: 0.10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10 mg/kg vecuronium
Study: 2576216
Drug: 0.20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.20 mg/kg vecuronium
Study: 30095728
Drug: Bedtime administration
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime administration of aspirin (100 mg)
Study: 30095728
Drug: Daytime administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daytime administration of aspirin (100 mg)
Study: 25678774
Drug: Oxycodone once-a-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone once-a-day controlled-release (CR) tablets (20 mg)
Study: 25678774
Drug: Commercial products
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial products (10 mg bis in die [bid])
Study: 24188685
Drug: Axitinib 5
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 5 mg twice daily plus modified FOLFOX-6
Study: 24188685
Drug: Axitinib 5
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 5 mg twice daily plus FOLFIRI
Study: 24188685
Drug: Bevacizumab 5
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5 mg/kg every 2 weeks plus modified FOLFOX-6
Study: 24188685
Drug: Bevacizumab 5
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5 mg/kg every 2 weeks plus FOLFIRI
Study: 21615341
Drug: Spinal bupivacaine
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal bupivacaine 10 mg (Group 1)
Study: 21615341
Drug: Ropivacaine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 10 mg (Group 2)
Study: 21615341
Drug: Ropivacaine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 10 mg with sufentanil 2.5 mcg (Group 3)
Study: 21615341
Drug: Ropivacaine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 10 mg with sufentanil 5 mcg (Group 4)
Study: 11426071
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (zidovudine/didanosine/nevirapine)
Study: 8960733
Drug: Tablet levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet levodopa/carbidopa (LD/CD)
Study: 3620048
Drug: Full-dose (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose (0.5 ml) intramuscular injection of PVRV on days 0, 3, 7, 14 and 28
Study: 3620048
Drug: 2-site intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-site intradermal injections of PVRV (0.1 ml) on days 0, 3, and 7, followed by another intradermal injection on day 28
Study: 3620048
Drug: 4-site intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-site intradermal injections of PVRV (0.1 ml) on days 0, 3, and 7, followed by another intradermal injection on day 28
Study: 3620048
Drug: 1-site intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-site intradermal injections of PVRV (0.1 ml) on days 0, 3, and 7, followed by another intradermal injection on day 28
Study: 29203380
Drug: Periarticular injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection (PI)